Oxford BioMedica (GB:OXB) has released an update.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Oxford Biomedica Plc, a leading cell and gene therapy Contract Development and Manufacturing Organisation (CDMO), disclosed its total number of voting rights as 105,359,856 following the close of business on September 30, 2024. This figure is the denominator for shareholders to determine their notification requirements for any interest changes in the company. Oxford Biomedica, known for its pioneering efforts in viral vectors and gene therapies, continues to innovate in the industry with advanced manufacturing technologies and global facilities.
For further insights into GB:OXB stock, check out TipRanks’ Stock Analysis page.